High-risk prostate cancer is characterized by D’Amico criteria as any of the following—clinical stage T3a or higher, Gleason score 8 to 10, and pre-treatment prostate-specific antigen (PSA) > 20 ng/mL [2]. The gene discussed is KLK3; the disease is prostate carcinoma.